The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...
The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...
The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...
Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in ...
The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.
The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 ...
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately ...
The Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary disease (COPD ...
Dupixent approved in China as the first-ever biologic medicine for patients with COPDApproval follows EU approval of Dupixent for adults with ...